Lupin Q2 Results: Board to meet on November 8 to discuss unaudited results
₹1,144.90, against previous close of ₹1,168. Check our Markets LIVE coverage here On October 23, Lupin said it has received approval from the United States Food and Drug Adminstration (US FDA) to market its generic Fluconazole tablets used in the treatment of fungal infections, the company told the exchanges.
The approval is for he abbreviated new drug application of Fluconazole tablets in strengths of 50 mg, 100 mg, 150 mg and 200 mg, Lupin said. They will be manufactured at the company's Pithampurunit.
For Tech Mahindra Q3 Results check here These are the generic equivalents of Diflucan tablets, 50 mg, 100 mg, 150 mg, and 200 mg, of Pfizer Inc, it added. This product will be manufactured at Lupin's Pithampur facility in India, the company said.
Read more on livemint.com
